Alphanate

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Alphanate
Generic name
ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN)
Manufacturer
GRIFOLS USA, LLC
Product type
PLASMA DERIVATIVE
SPL set ID
5a7aea94-654c-4113-9014-c3137de0a931
SPL ID
62efdce0-9d8e-47ee-954c-9a4cbdfb525d
Version
29
Effective date
2026-08-25
Source export date
2026-11-13
Source partition
14
Source file
https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 18:18:22
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Anaphylaxis or severe hypersensitivity reactions have occurred. Discontinue treatment with ALPHANATE and administer appropriate emergency treatment should symptoms of anaphylaxis or severe hypersensitivity occur. ( 5.1 ) Neutralizing antibodies to Factor VIII and VWF have occurred. ( 5.2 ) Thromboembolic events (TE) have occurred in patients with VWD, especially with known risk factors. Monitor patients for signs and symptoms of TE. ( 5.3 ) Intravascular hemolysis may occur with infusion of large doses of FVIII/von Willebrand Factor Complex. Should this condition occur and lead to progressive hemolytic anemia, discontinue administration of ALPHANATE and consider alternative therapy. ( 5.4 ) Rapid administration may result in vasomotor reactions. ( 5.5 ) ALPHANATE is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.6 ) Perform assays to determine if FVIII/VWF inhibitors are present. ( 5.7 ) 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions including anaphylaxis have occurred during or after ALPHANATE administration. Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. Discontinue use of ALPHANATE if hypersensitivity symptoms occur and initiate appropriate treatment. 5.2 Neutralizing Antibodies Neutralizing antibodies (inhibitors) to von Willebrand Factor and Factor VIII have occurred following administration of ALPHANATE. Monitor patients for the development of neutralizing antibodies by appropriate clinical observations and laboratory tests. If expected plasma FVIII/VWF activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an appropriate assay that measures FVIII/VWF inhibitor concentration. 5.3 Thromboembolic Events Thromboembolic events have been reported with ALPHANATE administration [see Adverse Reactions (6) ]. Risk factors for thromboembolic events include patients with von Willebrand Disease, elderly age, previous thrombosis, metabolic syndrome, cancer, surgery, oral contraceptive and hormone therapy, diabetes, hypertension, hyperlipidemia, smoking, and pregnancy. Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, during continued treatment with ALPHANATE. Consider antithrombotic measures in patients with at risk for thrombosis. [see Monitoring: Laboratory Tests (5.7) ] . 5.4 Intravascular Hemolysis Intravascular hemolysis may occur following treatment with ALPHANATE as it contains blood group specific isoagglutinins. Risk factors for hemolysis include large and/or frequent doses of ALPHANATE in patients with blood groups A, B, or AB. Monitor patients for clinical signs and symptoms of hemolysis. If hemolysis occurs, pause infusion if ongoing and manage according to clinical practice. 5.5 Vasomotor Reactions Do not administer ALPHANATE at a rate exceeding 10 mL/minute. Rapid administration of ALPHANATE may result in vasomotor reactions. 5.6 Transmissible Infectious Agents Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob Disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain virus infections, and by inactivating and/or removing certain viruses during manufacturing. [see Description (11) ]. 5.7 Monitoring: Laboratory Tests Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE. Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, particularly in patients with known risk factors.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions reported with ALPHANATE (incidence >1% of infusions) were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash and chills. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. Hemophilia A In a prospective clinical study with ALPHANATE, 23 patients were exposed to 1217 infusions (median=42, range 2 to 160). The total number of exposure days was 1133, and the total number of months on study across all patients was 234 (19.5 patient years). von Willebrand Disease (VWD) In the prospective clinical study of ALPHANATE[using both ALPHANATE Solvent Detergent (A-SD, a previous generation product) and ALPHANATE Solvent Detergent/Heat Treated (A-SD/HT, the current generation product)] in patients with VWD, adverse reactions occurred in 5 of 36 patients (13.9%) treated with ALPHANATE (A-SD/HT). Sixty-one total adverse reactions were reported in 204 infusions. The majority of adverse reactions were rated as mild (55 of 61 [90.2%]) and six (9.8%) were rated as moderate. Overall, the proportion of infusions associated with adverse reactions was 14 of 204 infusions (6.9%). The most common adverse reactions reported (> 1% of infusions) were pruritus, headache, backpain, paresthesia, respiratory distress, facial edema, pain, rash, and chills. One incident of pulmonary embolism was reported that was considered to have a possible relationship to the product. This patient received a dose of 60 IU VWF:RCo/kg body weight and the FVIII:C level achieved was 290%. In the retrospective study conducted to determine the efficacy and safety of ALPHANATE (A-SD/HT) in a surgical or invasive procedure setting as perioperative prophylaxis against excessive bleeding [see Clinical Studies (14) ], 3 out of 39 patients (7.7%) experienced 6 adverse reactions. Four were considered mild and 2 were considered moderate adverse reactions. The adverse reactions were pruritus, paresthesia (2 events) and hemorrhage, (all considered mild), and one event each of moderate hematocrit decrease and orthostatic hypotension. One adverse reaction (pain) related to the treatment with heat-treated ALPHANATE (A-SD/HT) was reported in the four pediatric patients with VWD during the course of the prospective study and in none of the five pediatric patients in the retrospective clinical study. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during postmarketing use of ALPHANATE: General disorders and administration site conditions: fever, fatigue, and infusion site pain Gastrointestinal disorders: nausea Musculoskeletal and connective tissue disorders: joint pain Immune system disorders: allergic/hypersensitivity reactions

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.